Table 2

Association between TSH and markers of disease severity

Relative to normal TSH (n=96)
Low TSH (n=10)High TSH (n=6)
95% CIP value95% CIP value
Hazard of mortality
 Unadjusted0.7 (0.1 to 5.0)0.694.5 (1.3 to 15.7)0.02
 Full0.8 (0.1 to 6.5)0.847.1 (1.8 to 28.5)0.006
 Full+NT-proBNP1.7 (0.2 to 14.2)0.645.2 (1.2 to 22.4)0.03
RV basal diameter (cm)
 Unadjusted−0.3 (−1.0 to 0.3)0.320.3 (−0.5 to 1.1)0.47
 Full−0.3 (−0.9 to 0.3)0.290.3 (−0.4 to 1.1)0.40
 Full+NT-proBNP−0.2 (−0.7 to 0.4)0.58−0.1 (−0.7 to 0.4)0.80
TAPSE (mm)
 Unadjusted3 (−1 to 7)0.14−4 (−9 to 1)0.15
 Full3 (0 to 7)0.08−4 (−9 to 1)0.14
 Full+NT-proBNP3 (−1 to 7)0.14−2 (−7 to 3)0.41
Walk distance (meters)
 Unadjusted64 (−9 to 137)0.09−84 (−171 to 4)0.06
 Full62 (−13 to 136)0.10−75 (−163 to 14)0.10
 Full+NT-proBNP56 (−11 to 122)0.10−16 (−99 to 66)0.70
NYHA Functional Class
 Unadjusted0.9 (0.2 to 4.7)0.854.3 (0.7 to 24.8)0.11
 Full0.8 (0.1 to 4.7)0.784.5 (0.6 to 31.5)0.13
 Full+NT-proBNP0.9 (0.1 to 7.7)0.923.3 (0.4 to 30.3)0.30
  • Full model accounted for differences in age, sex at birth and aetiology of pulmonary hypertension.

  • Hazard of mortality was estimated using Cox proportional hazards, RV basal diameter/TAPSE/walk distance were estimated using linear regression, the odds of NYHA Functional Class of III/IV relative to I/II were estimated using logistic regression.

  • Coefficients represent relationships between participants with high or low TSH relative to normal TSH (0.5–4.0).

  • Value in bold indicates statistically significant results.

  • NT-proBNP, N-terminal-pro hormone brain natriuretic peptide; NYHA, New York Heart Association; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TSH, thyroid-stimulating hormone.